The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy
Abstract
BACKGROUND: Hemoglobin increases have been associated with quality of life (QOL) improvements in anemic cancer patients treated with epoetin alfa, but intervention generally has been reserved for symptomatic anemia or hemoglobin < 10 g/dL. Relationships among hemoglobin, functional status, and patient reported QOL have not been well characterized. METHODS: Data from two open‐label, community‐based trials of epoetin alfa therapy that enrolled 4382 anemic cancer patients undergoing chemotherapy were used to evaluate the relationship between hemoglobin changes and QOL changes. The authors measured QOL using the Linear Analog Scale Assessment (LASA) and the more detailed, disease‐specific Functional Assessment of Cancer Therapy‐Anemia (FACT‐An) instrument. Analyses were performed to determine the incremental change in QOL associated with hemoglobin increases (1 g/dL increments). RESULTS: Cross‐sectional analyses showed a nonlinear relationship and significant positive correlation between high hemoglobin levels and high LASA and FACT‐An scores (r = 0.25 and 0.29, respectively, P < 0.01). Patients with hemoglobin increases of ≥ 2 g/dL reported statistically significant improvements in five FACT‐An items selected a priori specifically to reflect functional capacity. An incremental analysis used regression methods to identify the longitudinal relationship between incremental changes in hemoglobin and QOL scores. This relationship was found to be nonlinear, with the maximum QOL gain occurring at a hemoglobin level of 12 g/dL (range, 11–13 g/dL). Patients with low baseline QOL scores and longer time periods between baseline and final QOL assessments experienced significantly (P < 0.05) greater increases in overall QOL. Progressive disease at baseline, change in disease status from baseline to end of study, and increase in self‐reported pain or nausea all had significant (P < 0.05) negative effects on QOL scores. CONCLUSIONS: A direct relationship exists between hemoglobin increases during epoetin alfa therapy and corresponding QOL improvements in cancer patients receiving chemotherapy across the clinically relevant hemoglobin range of 8–14 g/dL. These data suggest that the maximal incremental gain in QOL occurs when hemoglobin is in the range of 11–13 g/dL. Cancer 2002;95:888–95. © 2002 American Cancer Society. DOI 10.1002/cncr.10763
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sample Selection Bias as a Specification Error
Heckman, J. J. (1979) · Econometrica · doi:10.2307/1912352 · Cited by 28,779
Quality of life and pharmacoeconomics in clinical trials
Pater, J. (1996) · Controlled Clinical Trials · doi:10.1016/s0197-2456(97)82191-5 · Cited by 2,395
Yellen, S. B., Cella, D. F., Webster, K., Blendowski, C., & Kaplan, E. (1997) · Journal of Pain and Symptom Management · doi:10.1016/s0885-3924(96)00274-6 · Cited by 1,964
Self-citationQuality of life and pharmacoeconomics in clinical trials
Spilker, B. (1996) · DigitalGeorgetown (Georgetown University Library) · Cited by 1,862
Serlin, R. C., Mendoza, T. R., Nakamura, Y., Edwards, K. R., & Cleeland, C. S. (1995) · Pain · doi:10.1016/0304-3959(94)00178-h · Cited by 1,494
Self-citationImpact of Cancer-Related Fatigue on the Lives of Patients: New Findings From the Fatigue Coalition
Curt, G. A., Breitbart, W., Cella, D., Groopman, J. E., Horning, S. J., Itri, L. M., Johnson, D. H., Miaskowski, C., Scherr, S. L., Portenoy, R. K., et al. (2000) · The Oncologist · doi:10.1634/theoncologist.5-5-353 · Cited by 1,248
Self-citationLittlewood, T. J., Bajetta, E., Nortier, J. W. R., Vercammen, E., Rapoport, B., & for the Epoetin Alfa Study Group (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.11.2865 · Cited by 974
Chemotherapy-Induced Anemia in Adults: Incidence and Treatment
Groopman, J. E., & Itri, L. M. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.19.1616 · Cited by 929
(1997) · PubMed · Cited by 762
Demetri, G. D., Kris, M., Wade, J., Degos, L., & Cella, D. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.10.3412 · Cited by 751
Self-citationGlaspy, J., Bukowski, R., Steinberg, D., Taylor, C., Tchekmedyian, S., & Vadhan-Raj, S. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.3.1218 · Cited by 693
Self-citationCella, D. F. (1997) · PubMed · Cited by 687
Self-citationDecreased Erythropoietin Response in Patients with the Anemia of Cancer
Miller, C. B., Jones, R. J., Piantadosi, S., Abeloff, M. D., & Spivak, J. L. (1990) · New England Journal of Medicine · doi:10.1056/nejm199006143222401 · Cited by 658
Symptom prevalence, characteristics and distress in a cancer population
Portenoy, R. K., Thaler, H. T., Kornblith, A. B., McCarthy Lepore, J., Friedlander-Klar, H., Coyle, N., Smart-Curley, T., Kemeny, N., Norton, L., Hoskins, W., et al. (1994) · Quality of Life Research · doi:10.1007/bf00435383 · Cited by 655
Gabrilove, J. L., Cleeland, C. S., Livingston, R. B., Sarokhan, B., Winer, E., & Einhorn, L. H. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.11.2875 · Cited by 595
Self-citationOn the choice between sample selection and two-part models
Leung, S. F., & Yu, S. (1996) · Journal of Econometrics · doi:10.1016/0304-4076(94)01720-4 · Cited by 488
Evans, R. W. (1990) · JAMA · doi:10.1001/jama.263.6.825 · Cited by 406
Factors influencing quality of life in cancer patients: anemia and fatigue.
Cella, D. F. (1998) · PubMed · Cited by 386
Self-citationProgress toward guidelines for the management of fatigue.
Cella, D. F., Peterman, A. H., Passik, S. D., Jacobsen, P. B., & BREITBART, W. S. (1998) · PubMed · Cited by 384
Self-citationAnderson, H., Hopwood, P., Stephens, R. J., Thatcher, N., Cottier, B., Nicholson, M., Milroy, R., Maughan, T. S., Falk, S. J., Bond, M. G., et al. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1307 · Cited by 338
Österborg, A., Brandberg, Y., Molostova, V., Iosava, G., Abdulkadyrov, K., Hedenus, M., & Messinger, D. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.08.131 · Cited by 310
Revicki, D. A., Brown, R. E., Feeny, D. H., Henry, D., Teehan, B. P., Rudnick, M. R., & Benz, R. L. (1995) · American Journal of Kidney Diseases · doi:10.1016/0272-6386(95)90122-1 · Cited by 254
Beusterien, K. M., Nissenson, A. R., Port, F. K., Kelly, M., Steinwald, B., & Ware, J. E. (1996) · Journal of the American Society of Nephrology · doi:10.1681/asn.v75763 · Cited by 217
Erythropoietin for anaemia in cancer patients
Abels, R. (1993) · European Journal of Cancer · doi:10.1016/s0959-8049(05)80281-3 · Cited by 185
Fosså, S. D., Slee, P. H. T., Brausi, M., Horenblas, S., Hall, R. R., Hetherington, J. W., Aaronson, N., de Prijck, L., & Collette, L. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.1.62 · Cited by 179
Quality of life in chronic anemia of cancer during treatment with recombinant human erythropoietin
Leitgeb, C., Pecherstorfer, M., Fritz, E., & Ludwig, H. (1994) · Cancer · doi:10.1002/1097-0142(19940515)73:10<2535::aid-cncr2820731014>3.0.co;2-5 · Cited by 167
Working capacity is increased following recombinant human erythropoietin treatment
Mayer, G., Thum, J., Cada, E. M., Stummvoll, H. K., & Graf, H. (1988) · Kidney International · doi:10.1038/ki.1988.213 · Cited by 159
Improvement of brain function in hemodialysis patients treated with erythropoietin
Grimm, G., Stockenhuber, F., Schneeweiß, B., Madl, C., Zeitlhofer, J., & Schneider, B. (1990) · Kidney International · doi:10.1038/ki.1990.229 · Cited by 156
Agteresch, H. J. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.4.321 · Cited by 154
* (1991) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(12)80290-3 · Cited by 133
Laupacis, A., Wong, C. J., & Churchill, D. N. (1991) · Controlled Clinical Trials · doi:10.1016/s0197-2456(05)80021-2 · Cited by 119
Hultborn, R., Gundersen, S., Rydén, S., Holmberg, E. C., Carstensen, J. M., Wallgren, U.-B., Killany, S., Andreassen, L., Carlsson, G. U., Fahl, N., et al. (1999) · PubMed · Cited by 115
Epoetin beta in the treatment of anemia in patients with advanced gastrointestinal cancer.
Glimelius, B. L. G., Linné, T., Hoffman, K., Larsson, L., Svensson, J.-H., Näsman, P., Svensson, B., & Helmers, C. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.434 · Cited by 82
Exercise in Hemodialysis Patients after Treatment with Recombinant Human Erythropoietin
Lundin, P., Akerman, M. J. H., Chesler, R., Delano, B. G., Goldberg, N., Stein, R. A., & Friedman, E. A. (2008) · The Nephron journals/Nephron journals · doi:10.1159/000186443 · Cited by 80
Harris, D. C. H., Lawrence, S., Chapman, J. R., Roger, S. D., & Stewart, J. H. (1991) · Australian and New Zealand Journal of Medicine · doi:10.1111/j.1445-5994.1991.tb01372.x · Cited by 42
Clinical Benefits of Epoetin Alfa Therapy in Patients with Lung Cancer
Crawford, J., Demetri, G. D., Gabrilove, J. L., Blasi, M. V., Sarokhan, B. J., & Glaspy, J. A. (2002) · Clinical Lung Cancer · doi:10.3816/clc.2002.n.001 · Cited by 36
Self-citationIncreased Risk of Cardiovascular Disease with Erythropoietin in Chronic Dialysis Patients
Iseki, K., Nishime, K., Uehara, H., Tokuyama, K., Toma, S., Yoshihara, K., Kowatari, T., Terukina, S., Osawa, A., & Fukiyama, K. (2008) · The Nephron journals/Nephron journals · doi:10.1159/000188803 · Cited by 32
Cited by
Resistance Exercise in Men Receiving Androgen Deprivation Therapy for Prostate Cancer
Segal, R. J., Reid, R. D., Courneya, K. S., Malone, S. C., Parliament, M. B., Scott, C. G., Venner, P. M., Quinney, H. A., Jones, L. W., Slovinec D’Angelo, M. E., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.09.534 · Cited by 786
Cancer‐related fatigue: Evolving concepts in evaluation and treatment
Stasi, R., Abriani, L., Beccaglia, P., Terzoli, E., & Amadori, S. (2003) · Cancer · doi:10.1002/cncr.11742 · Cited by 712
Iron, anaemia, and inflammatory bowel diseases
Gasche, C., Lomer, M. C. E., Cavill, I., & Weiss, G. (2004) · Gut · doi:10.1136/gut.2003.035758 · Cited by 494
Wright, J. R., Ung, Y. C., Julian, J. A., Pritchard, K. I., Whelan, T. J., Smith, C., Szechtman, B., Roa, W., Mulroy, L., Rudinskas, L., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.1514 · Cited by 428
Adès, L., Itzykson, R., & Fenaux, P. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61901-7 · Cited by 393
Metadata
- Authors
- Crawford, J., Cella, D., Cleeland, C. S., Cremieux, P., Demetri, G. D., Sarokhan, B. J., Slavin, M. B., & Glaspy, J. A.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2002-07-31
- Volume
- 95
- Issue
- 4
- Pages
- 888-895
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W1970997581
- Cited by
- 428
- References
- 38
- FWCI
- 16.18
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.